This differential of better patient survival associated with PR antagonist versus agonist treatment is consistent with the observed higher anti-tumor activity of tamoxifen combined with PR antagonists CDB4124 [1], CDB4453 and SPRM EC313 (Figure 5E) versus the cytostatic effect observed with the PR agonist progesterone [2]. This evidence concerns the gene PGR and neoplasm.